Diversified Healthcare Trust
NASDAQ:DHCREIT - Healthcare Facilities
+$0.25 today
- Market cap
- $1.76B
- Beta
- 2.29
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$1.33
- Dividend yield
- 0.45%
Volume 1.69M
Average 1.79M
DHC EBITDA Margin
EBITDA as a percentage of revenue.
Diversified Healthcare TrustNASDAQ: DHC
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to 15.6%
EBITDA Margin was 15.6% in Q1 FY2026, down 0.8 pp from a year earlier. On a trailing-twelve-month basis it was 10.8%, down 5.0 pp year over year. Over 3 fiscal years it narrowed by 21.5 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 3 analysts of 17.7% for the fiscal year ending Dec 2026, up from 11.9% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 15.6%-20.3 pp QoQ
- Last fiscal yearDec 2025
- 11.9%-3.5 pp YoY
- LTMMar 2026
- 10.8%-5.0 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -0.8 pp | +11.2 pp | +12.0 pp |
| 1 year | -3.5 pp | +5.9 pp | +9.4 pp |
| 3 years | -21.5 pp | +3.5 pp | +25.0 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 11.9%
- Year-over-year change
- -3.5pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.9% | -3.5pp |
| FY2024 | 2024-12-31 | 15.4% | +1.3pp |
| FY2023 | 2023-12-31 | 14.1% | -19.2pp |
| FY2022 | 2022-12-31 | 33.3% | -17.9pp |
| FY2021 | 2021-12-31 | 51.2% | — |
EBITDA Margin vs competitors
How DHC compares with its peers on the latest reported figures
- DHC's LTM Mar 2026 EBITDA Margin of 10.8% is the 6th highest of the 7 companies compared; the peer median is 38.5%.
- Its year-over-year change of -5.0 pp is the 4th highest of 7, against a peer median of -10.9 pp.
- Over three fiscal years its change of -21.5 pp compares with a peer median of -12.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 63.0% | +12.7 pp | +3.9 pp | |
| LTM Mar 2026 | 48.0% | -3.0 pp | -29.5 pp | |
| LTM Mar 2026 | 47.1% | -87.2 pp | +28.1 pp | |
| LTM Mar 2026 | 29.9% | +29.9 pp | +78.8 pp | |
| LTM Mar 2026 | 16.9% | -65.3 pp | -4616.1 pp | |
| LTM Mar 2026 | 10.8% | -5.0 pp | -21.5 pp | |
| LTM Mar 2026 | -4.1% | -18.8 pp | -54.8 pp | |
| Peer median (excluding DHC) | 38.5% | -10.9 pp | -12.8 pp | |
Competitors are the stored peer set for DHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.38B | 1.28B | 1.41B | 1.5B | 1.54B |
| Cost of Revenue | 1.09B | 1.11B | 1.19B | 1.24B | 1.78B |
| Gross Profit | 291.4M | 174.5M | 225.3M | 256.38M | (245.33M) |
| Gross Margin | 21.1% | 13.6% | 16.0% | 17.1% | -16.0% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 34.09M | 26.44M | 26.13M | 26.52M | 45.5M |
| Operating Expenses | 305.22M | 265.72M | 26.13M | 26.52M | (206.07M) |
| Depreciation & Amortization | 271.13M | 239.53M | 283.84M | 285.06M | 261.92M |
| EBITDA | 708.25M | 427.79M | 198.93M | 229.96M | 182.28M |
| EBITDA Margin | 51.2% | 33.3% | 14.1% | 15.4% | 11.9% |
| Operating Income | (13.82M) | (91.22M) | 199.17M | 229.86M | (39.27M) |
| Operating Margin | -1.0% | -7.1% | 14.1% | 15.4% | -2.6% |
| Interest Income | 20.64M | 15.93M | 15.54M | 8.95M | 0 |
| Interest Expense | 255.76M | 209.38M | 191.78M | 235.24M | 204.5M |
| Other Income / Expenses | 195.17M | 76.16M | (492.3M) | (599.65M) | (244.88M) |
| Income Before Tax | 181.36M | (15.06M) | (293.13M) | (369.79M) | (284.14M) |
| Pre-Tax Margin | 13.1% | -1.2% | -20.8% | -24.7% | -18.5% |
| Income Tax Expense | 1.43M | 710K | 445K | 467K | 1.74M |
| Net Income | 174.52M | (15.77M) | (293.57M) | (370.26M) | (285.89M) |
| Net Margin | 12.6% | -1.2% | -20.8% | -24.8% | -18.6% |
| EPS (Basic) | 0.73 | (0.07) | (1.23) | (1.55) | (1.19) |
| EPS (Diluted) | 0.73 | (0.07) | (1.23) | (1.55) | (1.19) |
| Weighted Avg Shares | 237.97M | 238.32M | 238.84M | 239.54M | 240.29M |
| Weighted Avg Shares (Diluted) | 237.97M | 238.31M | 238.84M | 239.54M | 240.29M |
Diversified Healthcare Trust
NASDAQ:DHC
Intrinsic Alpha fair value
Locked
Current Price
$7.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.